Lupus News

SAN DIEGO — Older individuals experience reduced immune activity and increased inflammation that often resemble rheumatic and autoimmune diseases, according to data presented at the Congress of Clinical Rheumatology West.

SAN DIEGO — Primary prevention remains the biggest treatment challenge in antiphospholipid syndrome, according to a speaker at the Congress of Clinical Rheumatology West.

In the 4 decades since 1976, the incidence and prevalence of lupus nephritis has increased among the population in Minnesota, according to data published in Arthritis Rheumatology.

SAN DIEGO — Limited assessment tools make it difficult to determine the prevalence and severity of cognitive disorders in patients with rheumatic and autoimmune diseases, according to a speaker at the Congress of Clinical Rheumatology West.

SAN DIEGO — New drugs for the management of systemic lupus erythematosus and lupus nephritis may help bridge the gap of current unmet needs among patients, according to a speaker at the Congress of Clinical Rheumatology West.

Pre-exposure prophylaxis with Evusheld, combined with aggressive outpatient treatment, may reduce COVID-19 severity in patients with immune-mediated inflammatory disease on B-cell depletion, according to a letter published in RMB Open.

Patients with systemic lupus erythematosus who achieve remission, regardless of treatment status, or low disease activity are less likely to accrue as much systematic damage as those who do not reach treatment goals, according to data.

Litifilimab is superior to placebo in improving CLASI-A scores among patients with cutaneous lupus erythematosus over 16 weeks, according to data published in the New England Journal of Medicine.

Litifilimab is superior to placebo in reducing tender and swollen joints among patients with systemic lupus erythematosus, according to phase 2 trial data published in the New England Journal of Medicine.

Patients with systemic lupus erythematous achieved an improved serological response following a booster COVID-19 vaccine dose, according to data collected during the omicron BA.1 wave in New York and published in The Lancet Rheumatology.